DarioHealth Corp. (DRIO)

Market Cap	148.17M
Revenue (ttm)	26.88M
Net Income (ttm)	-73.03M
Shares Out	25.68M
EPS (ttm)	-3.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	118,030
Open	5.72
Previous Close	5.67
Day's Range	5.57 - 5.94
52-Week Range	3.53 - 9.31
Beta	1.26
Analysts	Buy
Price Target	13.34 (+131.2%)
Earnings Date	Mar 28, 2023

About DRIO

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-s...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2011
• Employees: 200
• Stock Exchange: NASDAQ
• Ticker Symbol: DRIO

Financial Performance

In 2021, DarioHealth's revenue was $20.51 million, an increase of 170.76% compared to the previous year's $7.58 million. Losses were -$78.77 million, 137.9% more than in 2020.

Analyst Forecast

According to 11 analysts, the average rating for DRIO stock is "Buy." The 12-month stock price forecast is $13.34, which is an increase of 131.20% from the latest price.

Price Target

$13.34

(131.20% upside)

Analyst Consensus: Buy